What is Halozyme Thrp's earnings per share (EPS)?

Halozyme Thrp (HALO) reported diluted earnings per share of $2.56 for fiscal year 2025. This represents a -25.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Halozyme Thrp Financials

HALO

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Halozyme Thrp (HALO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 81/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Halozyme Thrp has an operating margin of 33.6%, meaning the company retains $34 of operating profit per $100 of revenue. This strong profitability earns a score of 97/100, reflecting efficient cost management and pricing power. This is down from 54.3% the prior year.

Growth

Halozyme Thrp's revenue surged 37.6% year-over-year to $1.4B, reflecting rapid business expansion. This strong growth earns a score of 96/100.

Leverage

Halozyme Thrp has elevated debt relative to equity (D/E of 43.89), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

With a current ratio of 4.66, Halozyme Thrp holds $4.66 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 93/100.

Cash Flow

100

Halozyme Thrp converts 46.2% of revenue into free cash flow ($644.6M). This strong cash generation earns a score of 100/100.

Returns

100

Halozyme Thrp earns a strong 649.2% return on equity (ROE), meaning it generates $649 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from 122.1% the prior year.

Altman Z-Score Safe

3.36

Halozyme Thrp scores 3.36, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($7.7B) relative to total liabilities ($2.5B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

5/9

Halozyme Thrp passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

2.06x

For every $1 of reported earnings, Halozyme Thrp generates $2.06 in operating cash flow ($651.6M OCF vs $316.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

25.9x

Halozyme Thrp earns $25.9 in operating income for every $1 of interest expense ($469.0M vs $18.1M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.4B

YoY+37.6%

5Y CAGR+39.2%

10Y CAGR+26.3%

Halozyme Thrp generated $1.4B in revenue in fiscal year 2025. This represents an increase of 37.6% from the prior year.

EBITDA

$480.4M

YoY-14.5%

5Y CAGR+26.6%

Halozyme Thrp's EBITDA was $480.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.5% from the prior year.

Net Income

$316.9M

YoY-28.6%

5Y CAGR+19.7%

Halozyme Thrp reported $316.9M in net income in fiscal year 2025. This represents a decrease of 28.6% from the prior year.

EPS (Diluted)

$2.56

YoY-25.4%

5Y CAGR+23.0%

Halozyme Thrp earned $2.56 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 25.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$644.6M

YoY+37.6%

5Y CAGR+64.8%

Halozyme Thrp generated $644.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 37.6% from the prior year.

Cash & Debt

$133.8M

YoY+15.5%

5Y CAGR-2.0%

10Y CAGR+11.9%

Halozyme Thrp held $133.8M in cash against $2.1B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

118M

YoY-4.2%

5Y CAGR-2.7%

10Y CAGR-0.8%

Halozyme Thrp had 118M shares outstanding in fiscal year 2025. This represents a decrease of 4.2% from the prior year.

Margins & Returns

Gross Margin

83.6%

YoY-0.7pp

5Y CAGR-0.2pp

10Y CAGR+5.3pp

Halozyme Thrp's gross margin was 83.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.7 percentage points from the prior year.

Operating Margin

33.6%

YoY-20.7pp

5Y CAGR-20.3pp

10Y CAGR+53.9pp

Halozyme Thrp's operating margin was 33.6% in fiscal year 2025, reflecting core business profitability. This is down 20.7 percentage points from the prior year.

Net Margin

22.7%

YoY-21.1pp

5Y CAGR-25.6pp

10Y CAGR+46.6pp

Halozyme Thrp's net profit margin was 22.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 21.1 percentage points from the prior year.

Return on Equity

649.2%

YoY+527.1pp

5Y CAGR+563.7pp

10Y CAGR+724.1pp

Halozyme Thrp's ROE was 649.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 527.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$81.5M

YoY+3.1%

5Y CAGR+18.9%

10Y CAGR-1.3%

Halozyme Thrp invested $81.5M in research and development in fiscal year 2025. This represents an increase of 3.1% from the prior year.

Share Buybacks

$342.4M

YoY+36.9%

5Y CAGR+17.9%

Halozyme Thrp spent $342.4M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 36.9% from the prior year.

Capital Expenditures

$7.0M

YoY-34.8%

5Y CAGR+22.7%

10Y CAGR+11.4%

Halozyme Thrp invested $7.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 34.8% from the prior year.

HALO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.4B+37.6%	$1.0B+22.4%	$829.3M+25.6%	$660.1M+48.9%	$443.3M+65.7%	$267.6M
Cost of Revenue	$228.8M+43.5%	$159.4M-17.1%	$192.4M+38.1%	$139.3M+71.1%	$81.4M+87.7%	$43.4M
Gross Profit	$1.2B+36.4%	$855.9M+34.4%	$636.9M+22.3%	$520.8M+43.9%	$361.9M+61.4%	$224.2M
R&D Expenses	$81.5M+3.1%	$79.0M+3.5%	$76.4M+14.6%	$66.6M+86.7%	$35.7M+4.2%	$34.2M
SG&A Expenses	$207.1M+34.2%	$154.3M+3.5%	$149.2M+3.9%	$143.5M+185.2%	$50.3M+10.0%	$45.7M
Operating Income	$469.0M-15.0%	$551.5M+63.4%	$337.6M+26.2%	$267.5M-3.0%	$275.9M+91.3%	$144.3M
Interest Expense	$18.1M+0.2%	$18.1M-3.6%	$18.8M+10.7%	$16.9M+125.2%	$7.5M-63.1%	$20.4M
Income Tax	$150.0M+32.7%	$113.0M+69.4%	$66.7M+42.6%	$46.8M+130.3%	-$154.2M-71156.2%	$217K
Net Income	$316.9M-28.6%	$444.1M+57.7%	$281.6M+39.3%	$202.1M-49.8%	$402.7M+212.0%	$129.1M
EPS (Diluted)	$2.56-25.4%	$3.43+63.3%	$2.10+45.8%	$1.44-47.4%	$2.74+201.1%	$0.91

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$451.8M+27.5%	$354.3M+8.8%	$325.7M+23.0%	$264.9M-11.1%	$298.0M+2.7%	$290.1M+25.4%	$231.4M+18.1%	$195.9M
Cost of Revenue	$78.8M+42.6%	$55.2M+19.2%	$46.4M-4.2%	$48.4M+15.1%	$42.1M-14.9%	$49.4M+24.8%	$39.6M+39.8%	$28.3M
Gross Profit	$373.0M+24.7%	$299.0M+7.0%	$279.4M+29.1%	$216.5M-15.4%	$256.0M+6.4%	$240.7M+25.5%	$191.7M+14.4%	$167.6M
R&D Expenses	$31.9M+84.9%	$17.3M-1.7%	$17.5M+18.5%	$14.8M-27.6%	$20.4M+10.7%	$18.5M-12.3%	$21.0M+10.1%	$19.1M
SG&A Expenses	$77.0M+67.1%	$46.1M+10.8%	$41.6M-1.8%	$42.4M+0.3%	$42.2M+2.4%	$41.2M+15.5%	$35.7M+1.6%	$35.1M
Operating Income	-$92.9M-142.6%	$217.9M+7.6%	$202.4M+43.0%	$141.5M-19.4%	$175.5M+7.5%	$163.2M+39.2%	$117.2M+22.7%	$95.5M
Interest Expense	$4.9M+14.3%	$4.3M-2.2%	$4.4M-2.9%	$4.5M-0.3%	$4.5M+0.4%	$4.5M0.0%	$4.5M+0.4%	$4.5M
Income Tax	$40.7M-6.8%	$43.7M+9.9%	$39.8M+54.6%	$25.7M-37.5%	$41.2M+46.4%	$28.1M+14.9%	$24.5M+27.6%	$19.2M
Net Income	-$141.6M-180.8%	$175.2M+6.1%	$165.2M+39.9%	$118.1M-13.8%	$137.0M0.0%	$137.0M+46.9%	$93.2M+21.4%	$76.8M
EPS (Diluted)	N/A	$1.43+7.5%	$1.33+43.0%	$0.93	N/A	$1.05+45.8%	$0.72+20.0%	$0.60

HALO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.5B+22.4%	$2.1B+19.1%	$1.7B-5.9%	$1.8B+66.7%	$1.1B+90.4%	$579.9M
Current Assets	$825.2M-24.0%	$1.1B+45.4%	$746.4M+1.0%	$739.0M-20.2%	$926.3M+67.0%	$554.8M
Cash & Equivalents	$133.8M+15.5%	$115.8M-2.1%	$118.4M-49.5%	$234.2M+97.3%	$118.7M-19.6%	$147.7M
Inventory	$176.5M+24.4%	$141.9M+11.2%	$127.6M+27.4%	$100.1M+85.7%	$53.9M-11.3%	$60.7M
Accounts Receivable	$426.3M+47.9%	$288.2M+23.6%	$233.3M+24.8%	$187.0M+105.5%	$91.0M-6.9%	$97.7M
Goodwill	$580.4M+39.2%	$416.8M0.0%	$416.8M+1.9%	$409.0M	$0	N/A
Total Liabilities	$2.5B+45.7%	$1.7B+3.0%	$1.6B-1.3%	$1.7B+84.2%	$907.5M+111.6%	$428.9M
Current Liabilities	$177.1M+27.3%	$139.1M+23.7%	$112.5M-14.0%	$130.8M+11.6%	$117.1M-72.2%	$421.4M
Long-Term Debt	$2.1B+42.3%	$1.5B+0.4%	$1.5B+0.4%	$1.5B+89.6%	$787.3M	$0
Total Equity	$48.8M-86.6%	$363.8M+334.1%	$83.8M-50.6%	$169.8M-13.8%	$197.0M+30.4%	$151.0M
Retained Earnings	$54.8M-84.8%	$359.9M+297.4%	$90.5M-36.8%	$143.2M+343.1%	-$58.9M+87.6%	-$474.6M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$2.5B+13.7%	$2.2B+8.1%	$2.1B-6.5%	$2.2B+6.4%	$2.1B-2.6%	$2.1B+7.5%	$2.0B+6.9%	$1.8B
Current Assets	$825.2M-37.9%	$1.3B+18.4%	$1.1B-11.0%	$1.3B+16.3%	$1.1B-3.7%	$1.1B+14.1%	$987.8M+13.1%	$873.6M
Cash & Equivalents	$133.8M-68.1%	$419.7M+578.4%	$61.9M-64.9%	$176.3M+52.2%	$115.8M-24.9%	$154.3M-17.9%	$187.9M+14.1%	$164.6M
Inventory	$176.5M-5.0%	$185.8M+2.4%	$181.5M+10.1%	$164.9M+16.2%	$141.9M+8.0%	$131.4M-17.5%	$159.3M-5.5%	$168.5M
Accounts Receivable	$426.3M+24.1%	$343.5M+9.0%	$315.1M+3.6%	$304.0M+5.5%	$288.2M+5.5%	$273.1M+29.8%	$210.4M+13.5%	$185.3M
Goodwill	$580.4M+39.2%	$416.8M0.0%	$416.8M0.0%	$416.8M0.0%	$416.8M0.0%	$416.8M0.0%	$416.8M0.0%	$416.8M
Total Liabilities	$2.5B+44.2%	$1.7B-0.2%	$1.7B+0.4%	$1.7B+0.9%	$1.7B+2.1%	$1.7B-0.9%	$1.7B+1.0%	$1.7B
Current Liabilities	$177.1M-78.8%	$837.2M+523.5%	$134.3M-10.7%	$150.4M+8.1%	$139.1M+27.8%	$108.8M-18.4%	$133.4M+1.3%	$131.6M
Long-Term Debt	$2.1B+167.8%	$800.1M-47.0%	$1.5B+0.1%	$1.5B+0.1%	$1.5B+0.1%	$1.5B+0.1%	$1.5B+0.1%	$1.5B
Total Equity	$48.8M-90.3%	$503.9M+51.4%	$332.7M-31.0%	$482.3M+32.6%	$363.8M-19.6%	$452.7M+56.4%	$289.4M+62.8%	$177.8M
Retained Earnings	$54.8M-89.1%	$502.1M+39.1%	$361.0M-24.5%	$478.0M+32.8%	$359.9M-9.5%	$397.6M+52.6%	$260.6M+55.7%	$167.4M

HALO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$651.6M+36.0%	$479.1M+23.3%	$388.6M+61.8%	$240.1M-19.8%	$299.4M+440.0%	$55.5M
Capital Expenditures	$7.0M-34.8%	$10.7M-30.1%	$15.3M+218.0%	$4.8M+230.1%	$1.5M-41.8%	$2.5M
Free Cash Flow	$644.6M+37.6%	$468.4M+25.5%	$373.3M+58.6%	$235.3M-21.0%	$298.0M+462.8%	$53.0M
Investing Cash Flow	-$545.8M-107.8%	-$262.7M-171.1%	-$96.9M+80.1%	-$487.0M-19.9%	-$406.3M-618.5%	$78.4M
Financing Cash Flow	-$85.2M+61.1%	-$218.9M+46.4%	-$408.0M-212.6%	$362.4M+365.4%	$77.9M+173.3%	-$106.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$342.4M+36.9%	$250.0M-37.9%	$402.4M+101.2%	$200.0M-42.9%	$350.1M+133.2%	$150.1M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$219.0M+22.6%	$178.6M+79.1%	$99.7M-35.3%	$154.2M-13.6%	$178.5M+54.7%	$115.4M+106.8%	$55.8M-56.9%	$129.4M
Capital Expenditures	$1.4M-52.9%	$3.0M+93.9%	$1.6M+64.5%	$950K-68.9%	$3.1M+101.2%	$1.5M-41.2%	$2.6M-27.2%	$3.5M
Free Cash Flow	$217.6M+23.9%	$175.6M+78.9%	$98.1M-36.0%	$153.3M-12.6%	$175.4M+54.1%	$113.9M+114.0%	$53.2M-57.7%	$125.9M
Investing Cash Flow	-$741.8M-467.9%	$201.6M+137.8%	$84.8M+193.8%	-$90.4M-406.7%	$29.5M+117.6%	-$167.5M-298.4%	-$42.0M+49.2%	-$82.7M
Financing Cash Flow	$239.5M+1169.2%	-$22.4M+92.5%	-$299.0M-8902.3%	-$3.3M+98.7%	-$246.4M-1427.6%	$18.6M+95.7%	$9.5M+2039.1%	-$489K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0-100.0%	$38.9M	N/A	N/A	$250.0M	$0	$0	$0

HALO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	83.6%-0.7pp	84.3%+7.5pp	76.8%-2.1pp	78.9%-2.7pp	81.6%-2.1pp	83.8%
Operating Margin	33.6%-20.7pp	54.3%+13.6pp	40.7%+0.2pp	40.5%-21.7pp	62.2%+8.3pp	53.9%
Net Margin	22.7%-21.1pp	43.7%+9.8pp	34.0%+3.3pp	30.6%-60.2pp	90.8%+42.6pp	48.2%
Return on Equity	649.2%+527.1pp	122.1%-213.9pp	336.0%+217.0pp	119.0%-85.4pp	204.5%+119.0pp	85.5%
Return on Assets	12.6%-9.0pp	21.5%+5.3pp	16.3%+5.3pp	11.0%-25.5pp	36.5%+14.2pp	22.3%
Current Ratio	4.66-3.1	7.80+1.2	6.64+1.0	5.65-2.3	7.91+6.6	1.32
Debt-to-Equity	43.89+39.8	4.14-13.8	17.89+9.1	8.79+4.8	4.00+4.0	0.00
FCF Margin	46.2%+0.0pp	46.1%+1.1pp	45.0%+9.4pp	35.6%-31.6pp	67.2%+47.4pp	19.8%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	82.6%-1.8pp	84.4%-1.4pp	85.8%+4.0pp	81.7%-4.2pp	85.9%+2.9pp	83.0%+0.1pp	82.9%-2.7pp	85.5%
Operating Margin	-20.6%-82.1pp	61.5%-0.6pp	62.2%+8.7pp	53.4%-5.4pp	58.9%+2.6pp	56.3%+5.6pp	50.7%+1.9pp	48.8%
Net Margin	-31.3%-80.8pp	49.5%-1.3pp	50.7%+6.1pp	44.6%-1.4pp	46.0%-1.3pp	47.2%+6.9pp	40.3%+1.1pp	39.2%
Return on Equity	-290.1%-324.8pp	34.8%-14.9pp	49.6%+25.1pp	24.5%-13.2pp	37.7%+7.4pp	30.3%-1.9pp	32.2%-11.0pp	43.2%
Return on Assets	-5.6%-13.5pp	7.9%-0.2pp	8.0%+2.7pp	5.4%-1.3pp	6.6%+0.2pp	6.5%+1.7pp	4.7%+0.6pp	4.2%
Current Ratio	4.66+3.1	1.59-6.8	8.36-0.0	8.39+0.6	7.80-2.6	10.36+2.9	7.41+0.8	6.64
Debt-to-Equity	43.89+42.3	1.59-2.9	4.54+1.4	3.13-1.0	4.14+0.8	3.32-1.9	5.19-3.2	8.44
FCF Margin	48.2%-1.4pp	49.6%+19.4pp	30.1%-27.7pp	57.9%-1.0pp	58.9%+19.6pp	39.3%+16.3pp	23.0%-41.3pp	64.3%

Similar Companies

Verona Pharma VRNA

$9.2B

Moderna MRNA

$20.1B

Roivant Sciences ROIV

$19.8B

Madrigal Pharmac MDGL

$12.0B

Revolution Medicines, Inc. RVMD

$19.3B

Frequently Asked Questions

What is Halozyme Thrp's annual revenue?

Halozyme Thrp (HALO) reported $1.4B in total revenue for fiscal year 2025. This represents a 37.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Halozyme Thrp's revenue growing?

Halozyme Thrp (HALO) revenue grew by 37.6% year-over-year, from $1.0B to $1.4B in fiscal year 2025.

Is Halozyme Thrp profitable?

Yes, Halozyme Thrp (HALO) reported a net income of $316.9M in fiscal year 2025, with a net profit margin of 22.7%.

What is Halozyme Thrp's EBITDA?

Halozyme Thrp (HALO) had EBITDA of $480.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Halozyme Thrp have?

As of fiscal year 2025, Halozyme Thrp (HALO) had $133.8M in cash and equivalents against $2.1B in long-term debt.

What is Halozyme Thrp's gross margin?

Halozyme Thrp (HALO) had a gross margin of 83.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Halozyme Thrp's operating margin?

Halozyme Thrp (HALO) had an operating margin of 33.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Halozyme Thrp's net profit margin?

Halozyme Thrp (HALO) had a net profit margin of 22.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Halozyme Thrp's return on equity (ROE)?

Halozyme Thrp (HALO) has a return on equity of 649.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Halozyme Thrp's free cash flow?

Halozyme Thrp (HALO) generated $644.6M in free cash flow during fiscal year 2025. This represents a 37.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Halozyme Thrp's operating cash flow?

Halozyme Thrp (HALO) generated $651.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Halozyme Thrp's total assets?

Halozyme Thrp (HALO) had $2.5B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Halozyme Thrp's capital expenditures?

Halozyme Thrp (HALO) invested $7.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Halozyme Thrp spend on research and development?

Halozyme Thrp (HALO) invested $81.5M in research and development during fiscal year 2025.

Does Halozyme Thrp buy back shares?

Yes, Halozyme Thrp (HALO) spent $342.4M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Halozyme Thrp have outstanding?

Halozyme Thrp (HALO) had 118M shares outstanding as of fiscal year 2025.

What is Halozyme Thrp's current ratio?

Halozyme Thrp (HALO) had a current ratio of 4.66 as of fiscal year 2025, which is generally considered healthy.

What is Halozyme Thrp's debt-to-equity ratio?

Halozyme Thrp (HALO) had a debt-to-equity ratio of 43.89 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Halozyme Thrp's return on assets (ROA)?

Halozyme Thrp (HALO) had a return on assets of 12.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Halozyme Thrp's Altman Z-Score?

Halozyme Thrp (HALO) has an Altman Z-Score of 3.36, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Halozyme Thrp's Piotroski F-Score?

Halozyme Thrp (HALO) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Halozyme Thrp's earnings high quality?

Halozyme Thrp (HALO) has an earnings quality ratio of 2.06x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Halozyme Thrp cover its interest payments?

Halozyme Thrp (HALO) has an interest coverage ratio of 25.9x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Halozyme Thrp?

Halozyme Thrp (HALO) scores 81 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.